SecBot SecBot
S-1/A ·Filed Apr 27, 2026

COAG

Hemab Therapeutics Holdings, Inc.
MIXED
Impact 6/10
Horizonmonths Processed6mo ago SEC0001193125-26-178809
IPO registration amendment
Actionable Insight ◆ Mixed

Monitor upcoming clinical data readouts for sutacimig in late 2026/early 2027, as success could validate the company's approach but failure would significantly impact the stock. Watch for updates on the remediation of material weaknesses in internal controls, as unresolved issues could delay financial reporting.

DirectionMixed
Confidencehigh
Horizonmonths

Executive Summary

Hemab Therapeutics Holdings, Inc. (COAG) is a clinical-stage biotech company developing therapies for rare blood coagulation disorders. Its lead asset, sutacimig, showed a 47% reduction in bleeding events in a Phase 1/2 trial for Glanzmann thrombasthenia, with data from a Phase 2 trial for Factor VII deficiency expected in late 2026. The company plans to use $180.3 million in IPO proceeds to fund clinical development, but faces significant risks including a history of increasing losses, serious adverse events of thrombosis in trials, and a material weakness in its internal controls.

Key Financial Metrics

Price Range
$16.00-$18.00

Key Facts

  • Company is developing therapies for rare blood coagulation disorders like Glanzmann thrombasthenia and Factor VII deficiency.
  • Lead asset sutacimig showed a 47% reduction in mean annualized treated bleed rate in a Phase 1/2 trial for Glanzmann thrombasthenia.
  • Company raised $180.3 million in net proceeds from its IPO to fund clinical development of its product candidates.
  • Serious adverse events of thrombosis were identified in the development of sutacimig, including one grade 2 proximal deep vein thrombotic event.
  • Company has identified material weaknesses in its internal control over financial reporting.
  • Net losses increased from $48.7 million in 2024 to $63.9 million in 2025.

Financial Impact

The company raised $180.3 million in net proceeds from its IPO to fund clinical development, but has not generated any revenue and reported net losses of $63.9 million in 2025.

revenuenetIncomeuseOfProceeds

Risk Factors

  • Clinical development risks including serious adverse events of thrombosis observed in trials
  • Financial risks due to increasing net losses and dependence on future funding
  • Operational risks from material weaknesses in internal control over financial reporting

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-1/A Filing (Primary)0001193125-26-178809
Document: d50309dex11.htm0001193125-26-178809
Document: d50309dex107.htm0001193125-26-178809

Track record

19 reports on COAG

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
  5. Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
  6. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
  7. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
  8. Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
  9. May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
  10. May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026